MC
CRSP icon

Moors & Cabot’s CRISPR Therapeutics CRSP Stock Holding History

Moors & Cabot’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,200
Closed -$5.16K – 928
2023
Q4 		$5.16K Buy
+1,200
New +$66.3K ﹤0.01% 831
2021
Q3 		– Sell
-2,100
Closed -$32K – 876
2021
Q2 		$32K Buy
2,100
+1,700
+425% +$207K ﹤0.01% 797
2021
Q1 		$11K Buy
+400
New +$60.4K ﹤0.01% 754

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Moors & Cabot's CRSP Position: Q2 2026 in Review

Moors & Cabot increased its CRISPR Therapeutics (CRSP) stake by 36% in Q2 2026, buying an estimated $93.6K and bringing the position to 6,732 shares worth $367K. The position accounts for 0.01% of the portfolio, ranked #667.

Moors & Cabot first reported a position in CRSP in Q1 2021 and has held it in 10 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Moors & Cabot held 6,732 shares of CRISPR Therapeutics worth $367K as of Q2 2026.
  • Moors & Cabot bought 1,775 CRISPR Therapeutics shares in Q2 2026, an estimated $93.6K.
  • CRISPR Therapeutics made up 0.01% of Moors & Cabot's portfolio in Q2 2026, its #667 holding.
  • Moors & Cabot first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.